BioCryst Pharmaceuticals Inc

BioCryst Pharmaceuticals faces a tough year: low stock, red earnings, but still pursuing rare‑disease treatments.

BioCryst Pharmaceuticals: Explore its rare‑disease drug pipeline, 2026 market performance, and Nasdaq outlook for biotech investors.

BioCryst’s pediatric approval of Orladeyo unlocks a larger NF1 patient base, boosting revenue prospects and driving analyst price targets higher.

BioCryst Pharmaceuticals pioneers oral, small‑molecule drugs for rare enzyme‑related diseases, balancing biotech volatility with a $1.49 billion market cap and a mission to transform unmet medical needs.

BioCryst Pharmaceuticals Inc. has reported a 50% surge in revenue and exceeded earnings expectations in Q2 2025, driven by strong demand for its flagship product ORLADEYO.

BioCryst Pharmaceuticals’ stock price surged 23% to a 16-month high after strong Q1 2025 earnings results, driven by robust sales of its key product ORLADEYO and strategic debt reduction efforts.

BioCryst Pharmaceuticals Inc. saw its stock surge 23% after strong Q1 earnings results, driven by robust sales of its flagship product ORLADEYO and strategic moves to reduce debt.

BioCryst Pharmaceuticals Inc. shares surged 23% after strong Q1 results and optimistic outlook, driven by increased ORLADEYO sales and positive analyst price target adjustments.

BioCryst Pharmaceuticals appoints Steve Frank to its Board of Directors, bolstering leadership as the company continues to develop novel treatments for rare diseases, including its oral complement factor B inhibitor FABHALTA.

BioCryst Pharmaceuticals Inc. is navigating a complex biotech landscape, with its upcoming earnings report and investor conferences set to shape its market trajectory, driven by its innovative pipeline and potential for its complement inhibitor FABHALTA.